Skip to main content

Table 1 Demographic and clinical characteristics of the study groups

From: The antipyretic efficacy and safety of propacetamol compared with dexibuprofen in febrile children: a multicenter, randomized, double-blind, comparative, phase 3 clinical trial

Characteristics

Study groups (n = 125)

Control group (n = 138)

p-value

Gender, male (%)

63 (50.4)

70 (50.7)

0.957

Age (years)

3.0 [0–14.0]

3.0 [0–13.0]

0.730

 0.5–1 year (%)

35 (28.0)

41 (29.7)

0.700

 2–5 years (%)

65 (52.0)

68 (49.3)

 6–10 years (%)

20 (16.0)

26 (18.8)

 11–14 years (%)

5 (4.0)

3 (2.2)

Weight (kg)

13.9 [7.4–88.0]

15.0 [7.5–51.0]

0.515

Baseline temperature (°C)

38.6 ± 0.5

38.7 ± 0.5

0.159

Laboratory test results (at admission)

 White blood cell count (× 103/μL)

9.7 [2.7–28.3]

9.6 [1.9–27.7]

0.555

 Neutrophil (%)

60.0 [7.7–91.0]

63.7 [16.9–95.0]

0.208

 Lymphocyte (%)

29.1 [4.0–86.8]

24.8 [2.0–73.2]

0.134

 Platelet (×103/μL)

246.0 [102.0–583.0]

251.0 [91.0–504.0]

0.824

 C-reactive protein (mg/μL)

1.68 [0.1–105.1]

2.33 [0.1–139.1]

0.486

  1. Results are presented as median [range] or as mean ± standard deviation or as a percentage (%)